7.5 USD
-0.08 (-1.06%)
7.5 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 82% to FDMT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 33.77. This target is 350.31% above the current price.
FDMT was analyzed by 17 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about FDMT.
In the previous month the buy percentage consensus was at a similar level.
FDMT was analyzed by 17 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-12-18 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-11-11 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-11-11 | Barclays | Maintains | Overweight -> Overweight |
| 2025-10-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-08-12 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-12 | Roth Capital | Maintains | Buy -> Buy |
| 2025-08-01 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-07-03 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-05-09 | Barclays | Maintains | Overweight -> Overweight |
| 2025-05-09 | Goldman Sachs | Maintains | Buy -> Buy |
| 2025-03-10 | B of A Securities | Maintains | Buy -> Buy |
| 2025-03-04 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-03 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-03-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-02-11 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-02-10 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-01-13 | Leerink Partners | Maintains | Outperform -> Outperform |
| 2025-01-13 | Morgan Stanley | Maintains | Underweight -> Underweight |
| 2025-01-13 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-18 | B of A Securities | Maintains | Buy -> Buy |
| 2024-11-21 | Morgan Stanley | Initiate | Underweight |
| 2024-11-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-14 | RBC Capital | Maintains | Outperform -> Outperform |
| 2024-11-14 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-23 | Cantor Fitzgerald | Downgrade | Overweight -> Neutral |
| 2024-09-19 | Leerink Partners | Reiterate | Outperform -> Outperform |
| 2024-09-19 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-09-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
4D MOLECULAR THERAPEUTICS IN / FDMT FAQ
Can you provide the average price target for 4D MOLECULAR THERAPEUTICS IN stock?
17 analysts have analysed FDMT and the average price target is 33.77 USD. This implies a price increase of 350.31% is expected in the next year compared to the current price of 7.5.
What is the consensus rating for 4D MOLECULAR THERAPEUTICS IN (FDMT) stock?
The consensus rating for 4D MOLECULAR THERAPEUTICS IN (FDMT) is 82.3529 / 100 . This indicates that analysts generally have a positive outlook on the stock.